Find out about SPIRIT IV 1-Year Results from TCT 2009

Find out about SPIRIT III 3-Year Results from TCT 2009

Find out about SPIRIT II & III 2-Year Meta-Analysis from TCT 2008

Find out about SPIRIT V 1-Year Results from PCR 2009

XIENCE V—a DES with superior* outcomes that can take your performance to new heights. Abbott’s XIENCE V is truly a next-generation DES, combining the proven deliverability of the MULTI-LINK VISION stent platform with a fluorinated copolymer and everolimus to deliver superior* outcomes for patients with coronary artery disease (CAD).

See how XIENCE V offers superior outcomes for patients with CAD

Learn about the proven design of XIENCE V: Deliverable, Effective, and Safe

* XIENCE V has demonstrated statistical superiority in the primary endpoints of SPIRIT IV, SPIRIT III and SPIRIT II in target lesion failure, in-segment late loss and in-stent late loss respectively. Source: SPIRIT IV 1-year results, Gregg Stone, TCT 2009 and XIENCE V IFU. TAXUS Express was the control in SPIRIT IV.

TAXUS, TAXUS Liberte, and TAXUS Express are registered trademarks of Boston Scientific and its affiliates.